Harmony Biosciences has named Adam Zaeske its next chief commercial officer, luring the Takeda veteran back from Europe to ...

Takeda Pharmaceutical has a robust drug discovery pipeline to meet future clinical demand. Check out the upside and downside ...

Takeda’s revamped R&D strategy means the drugmaker’s oncology leaders are prioritizing work in tumors across thoracic, ...

Rio Takeda of Japan shot a 3-under 69 to hold a two-shot lead after three rounds of the LPGA’s Blue Bay tournament on China’s southern island of Hainan.

Takeda is sharpening its oncology focus amid an R&D revamp. Sun Pharma will acquire Checkpoint Therapeutics and an ...

Farther Finance Advisors LLC boosted its position in Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report) by 123.6% during the fourth quarter, Holdings Channel reports. The institutional ...

− All four key secondary endpoints were met, including EU primary endpoint and patient-reported outcomes NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Protagonist ...

M&T Bank Corp lowered its position in Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report) by 10.0% in the 4th ...

SANYA, China (AP) — Rio Takeda shot a blistering 8-under 64 on Sunday to win the LPGA's Blue Bay tournament by six shots ahead of Minjee Lee of Australia, the second LPGA title for the young Japanese.

In previous years, Takeda Pharmaceutical Co. would draw attention to Rare Disease Day on the last day of February by doing the usual things that drug companies do: host podcasts and panel ...

Japanese Rio Takeda dominated the Blue Bay LPGA, winning with 271 (69 69 69 64, -17) shots, six ahead of Australian Minjee ...